Breast cancers with BRCA1 mutations include many TNBCs, however PARP inhibitors have not shown a direct correlation of effectiveness directly related to BRCA1 and BRCA2 mutations in TNBCs.36 MDA-MB-468 cells and HCC70 cells do not have BRCA mutations and they are more sensitive to PARP inhibitors than some breast cancer cell lines that have BRCA mutations. The gene discussed is BRCA2; the disease is breast cancer.